Science & Enterprise subscription

Follow us on Twitter

  • A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial p… https://t.co/iByygVnB9U
    about 17 hours ago
  • New post on Science and Enterprise: Covid-19 Drug Biotech Raises $300M in IPO https://t.co/zwkRakiFk5 #Science #Business
    about 17 hours ago
  • The Food and Drug Administration plans to use organ-on-chip models to test mechanisms for preventing Covid-19 infec… https://t.co/9zAfSK9Nnt
    about 22 hours ago
  • New post on Science and Enterprise: FDA to Use Lung Chip Model for Covid-19 Testing https://t.co/YGwasY1UUJ #Science #Business
    about 22 hours ago
  • Interim results from a clinical trial show a synthetic antibody drug reduces viral burden and medical visits among… https://t.co/bm7JdQ83hT
    about 2 days ago

Please share Science & Enterprise

AstraZeneca Consolidates Research in U.K. and U.S.

Pascal Soriot (AstraZeneca UK Ltd)

The pharmaceutical company AstraZeneca will consolidate its research operations at three main hubs in its U.K. home base, as well as the U.S. and continental Europe. The four-year plan, which includes moving its corporate headquarters, is expected to cost the company $1.4 billion and result in a reduction . . . → Read More: AstraZeneca Consolidates Research in U.K. and U.S.

Novartis to Close U.K. Plant, Consolidate R&D Sites

The pharmaceutical company Novartis, headquartered in Basel, Switzerland, says it has begun talks to close its factory in Horsham, U.K. and consolidate its R&D facilities in Europe. According to the Financial Times, Novartis will continue its other U.K. plants in Grimsby, Liverpool, and Dundee.

Closing the Horsham plant will mean the loss of 550 jobs, . . . → Read More: Novartis to Close U.K. Plant, Consolidate R&D Sites

Pfizer Slashes R&D Funding, Closes U.K. Research Site

Pfizer Inc. in New York said today it plans to cut its research and development spending to keep R&D costs in line with lower expected revenues in 2012. The reductions, which Pfizer calls “significant,” include closing its research facility in Sandwich, U.K. and consolidating research operations in the northeast U.S.

The company has lowered its . . . → Read More: Pfizer Slashes R&D Funding, Closes U.K. Research Site

Danish Pharma Company Restructures, Cuts Workforce

NeuroSearch, a biopharmaceutical company in Copenhagen, Denmark said today the company would restructure its operations to focus more on developing drugs for the central nervous system. This reorganization of the enterprise, says NeuroSearch, will lead to a 20 percent reduction in its workforce.

The goal of the restructuring is to accelerate development of its lead . . . → Read More: Danish Pharma Company Restructures, Cuts Workforce

Sanofi Aventis to Close Pennsylvania R&D Center

The Pottstown Mercury reports today that pharmaceutical company Sanofi Aventis, based in France, will close its Great Valley, Pennsylvania research and development site by July 2011. The Mercury says Sanofi Aventis will keep clinical supply and related support activities at the Great Valley site.

Elizabeth Baxter, a spokesperson for Sanofi Aventis, told the Mercury that . . . → Read More: Sanofi Aventis to Close Pennsylvania R&D Center

Cypress Bioscience to Cut Business Lines, Slash Workforce

Cypress Bioscience in San Diego, California announced today several cost-cutting measures including a sharp reduction in staff. The steps announced will end a co-promotion agreement with Forest Laboratories, and close the company’s personalized testing services.

The drug development company discontinued an agreement with Forest Laboratories to co-promote Savella, its drug for fibromyalgia, a disorder causing . . . → Read More: Cypress Bioscience to Cut Business Lines, Slash Workforce